Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III

Nick M. Spirtos, Lloyd H Smith, Nelson N H Teng

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.

Original languageEnglish (US)
Pages (from-to)34-38
Number of pages5
JournalGynecologic Oncology
Volume37
Issue number1
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Interferons
Gels
Neoplasms
Nonoxynol
Therapeutics
Cross-Over Studies
HIV
Biopsy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III. / Spirtos, Nick M.; Smith, Lloyd H; Teng, Nelson N H.

In: Gynecologic Oncology, Vol. 37, No. 1, 1990, p. 34-38.

Research output: Contribution to journalArticle

@article{a94592e7074f42bba391e621ed1eba44,
title = "Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III",
abstract = "Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5{\%} aqueous methycellulose base) with and without 1{\%} nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1{\%} nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43{\%}) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50{\%} reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30{\%}), 5 had PRs (50{\%}), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67{\%}) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.",
author = "Spirtos, {Nick M.} and Smith, {Lloyd H} and Teng, {Nelson N H}",
year = "1990",
doi = "10.1016/0090-8258(90)90303-3",
language = "English (US)",
volume = "37",
pages = "34--38",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Prospective randomized trial of topical α-interferon (α-interferon gels) for the treatment of vulvar intraepithelial neoplasia III

AU - Spirtos, Nick M.

AU - Smith, Lloyd H

AU - Teng, Nelson N H

PY - 1990

Y1 - 1990

N2 - Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.

AB - Twenty-one patients were prospectively randomized into a blinded double-armed crossover study comparing α-interferon (α-IFN, 106 IU in a 3.5% aqueous methycellulose base) with and without 1% nonoxynol-9. Nine and twelve patients were randomized to arms with (+N) and without (-N) 1% nonoxynol-9, respectively. Patients applied the gel to affected areas every 8 hr and were evaluated biweekly. Including those crossed over, 14 patients were treated with -N. Six of fourteen (43%) achieved complete responses: biopsy proven with at least 1 year follow-up (CR). One patient achieved a partial response with at least a 50% reduction in the total surface area of all lesions present (PR). Similarly, 13 patients were treated with +N. Two patients in this group were found to have invasive cancer and one to have HIV and thus were eliminated from statistical analysis. Of the remaining 10 patients, 3 had CRs (30%), 5 had PRs (50%), and 2 failed to respond. There was no significant difference in reponses between the two groups. Overall, 14 of 18 (67%) patients demonstrated some response to α-IFN applied topically. These data support the conclusion that α-IFN is an active agent in the treatment of vulvar intraepithelial neoplasia III.

UR - http://www.scopus.com/inward/record.url?scp=0025262422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025262422&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90303-3

DO - 10.1016/0090-8258(90)90303-3

M3 - Article

C2 - 2182407

AN - SCOPUS:0025262422

VL - 37

SP - 34

EP - 38

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -